TY - JOUR
T1 - Combination drug therapy for cryptosporidiosis in AIDS
AU - Smith, Nathaniel H.
AU - Cron, Stanley
AU - Valdez, Luis M.
AU - Chappell, Cynthia L.
AU - Clinton White, A.
N1 - Funding Information:
Received 28 January 1998; revised 21 April 1998. Presented: 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1998. Study design was approved by the Institutional Review Board of Baylor College of Medicine, and informed consent was obtained from all patients. Financial support: NIH (AI-07456 to N.H.S., AI-36221 to Baylor Center for AIDS Research), Environmental Protection Agency (824759), and Pfizer Pharmaceuticals. Azithromycin was provided by Pfizer Pharmaceuticals. Reprints or correspondence: Dr. A. Clinton White, Jr., Dept. of Medicine, Baylor College of Medicine, One Baylor Plaza, 561E, Houston, TX 77030 ([email protected]). *Present affiliation: Universidad Peruana ‘‘Cayetano Heredia,’’ Instituto de Medicina Tropical Alexander von Humboldt, Lima, Peru.
PY - 1998
Y1 - 1998
N2 - Aside from effective antiretroviral therapy, there is no consistently effective antiparasitic therapy for cryptosporidiosis in AIDS. The purpose of this study was to assess safety, efficacy, and durability of combination therapy with paromomycin and azithromycin for chronic cryptosporidiosis. Patients with AIDS, chronic cryptosporidiosis, and < 100 CD4 cells/μL were treated with open-label paromomycin (1.0 g twice a day) plus azithromycin (600 mg once a day) for 4 weeks, followed by paromomycin alone for 8 weeks. In 11 patients, median stool frequency decreased from 6.5/day (baseline) to 4.9/day (week 4) and 3.0/day (week 12). Median reductions in 24-h oocyst excretion were 84%, 95%, and >99% at 2, 4, and 12 weeks, respectively. None of the responses were attributable to antiretrovirals. Of 5 survivors at 12- 30 months of follow-up, 3 remain asymptomatic off medications, and 2 have chronic, mild diarrhea. Treatment of cryptosporidiosis with azithromycin and paromomycin was associated with significant reduction in oocyst excretion and some clinical improvement.
AB - Aside from effective antiretroviral therapy, there is no consistently effective antiparasitic therapy for cryptosporidiosis in AIDS. The purpose of this study was to assess safety, efficacy, and durability of combination therapy with paromomycin and azithromycin for chronic cryptosporidiosis. Patients with AIDS, chronic cryptosporidiosis, and < 100 CD4 cells/μL were treated with open-label paromomycin (1.0 g twice a day) plus azithromycin (600 mg once a day) for 4 weeks, followed by paromomycin alone for 8 weeks. In 11 patients, median stool frequency decreased from 6.5/day (baseline) to 4.9/day (week 4) and 3.0/day (week 12). Median reductions in 24-h oocyst excretion were 84%, 95%, and >99% at 2, 4, and 12 weeks, respectively. None of the responses were attributable to antiretrovirals. Of 5 survivors at 12- 30 months of follow-up, 3 remain asymptomatic off medications, and 2 have chronic, mild diarrhea. Treatment of cryptosporidiosis with azithromycin and paromomycin was associated with significant reduction in oocyst excretion and some clinical improvement.
UR - http://www.scopus.com/inward/record.url?scp=0031708185&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031708185&partnerID=8YFLogxK
U2 - 10.1086/515352
DO - 10.1086/515352
M3 - Article
C2 - 9728569
AN - SCOPUS:0031708185
SN - 0022-1899
VL - 178
SP - 900
EP - 903
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 3
ER -